Adeno-associated virus capable of expressing factor IX protein and cells comprising the same

Patent Citations (5)

Non-Patent Literature (42)

• Halene et al. Human Gene Therapy Jun. 2000; 11:1259-1267.Applicant
• Stocking et al. Bail Clin haematol Sep. 1997; 10:445-465.Applicant
• Blood Cells: Encyclopedia Britannica Online. Accessd Dec. 13, 2000.Applicant
• Orkin SH, et al. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.”, Dec. 7, 1995.Applicant
• Ohi et al, Gene 89:279-282, 1990.Applicant
• Nettelbeck et al. Gene therapy pp. 174-181 vol. 16 no 4 2000.Applicant
• Miller et al. progress in transcriptionally targeted and regulatable vectors for genetic therapy pp. 803-815 1997.Applicant
• Zink et al. Mammalian genome organization and its implications for the development of gene therapy vectors pp. 1-23 vol. 6 2001.Applicant
• Deonarain Ligand-targeted receptor-mediated vectors for gene delivery pp. 53-69 1998.Applicant
• Verma et al. Gene therapy promises,problems and prospects pp. 239-242 1997.Applicant
• Crystal Transfee of genes to humans:early lessons and obstacles to success 1995 vol. 270 p. 404-410.Applicant
• Hermonat et al., “Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells”, Proc. Natl. Acad. Sci. USA, vol. 81, pp. 6466-6470 (Oct. 1984).Applicant
• Tratschin et al., “A Human Parvovirus, Adeno-Associated Virus, as a Eucaryotic Vector: Transient Expression and Encapsidation of the Procaryotic Gene for Chloramphenicol Acetyltransferase”, Molecular and Cellular Bio., pp. 2072-2081 (Oct. 1984).Applicant
• Orkin, “Molecular Genetics and Potential Gene Therapy”, Clinical Immunology and Immunopathology, vol. 40, pp. 151-156 (1986).Applicant
• Nienhuis et al., “Transfer of Genes in Hematopoietic Cells with Retroviral Vectors”, Cell Physiology of Blood, Chapter 8, pp. 79-89 (1988).Applicant
• Wondisford et al., “Cloning of the Human Thyrotropin β-Subunit Gene and Transient Expression of Biologically Active Human Thyrotropin after Gene Transfection”, Molecular Endocrinology, vol. 2, No. 1, pp. 32-39 (1988).Applicant
• LaFace et al., “Gene Transfer into Hematopoietic Progenitor Cells Mediated by an Adeno-Associated Virus Vector”, Virology, vol. 162, pp. 483-486 (1988).Applicant
• Williams, “Gene Transfer and the Prospects for Somatic Gene Therapy”, Hematology/Oncology Clinics of North America, vol. 2, No. 2, pp. 277-287 (Jun. 1988).Applicant
• Gale, “Prospects for Correction of Thalassemia by Genetic Engineering”, Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches, pp. 141-159 (1989).Applicant
• Srivastava et al., “Construction of a recombinant human parvovirus B19: Adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus”, Proc. Natl. Acad. Sci. USA, vol. 86, pp. 8078-8082 (Oct. 1989).Applicant
• Sorrentino et al., “A 46 base pair enhancer sequence within the locus activating region is required for induced expression of the gamma-globin gene during erythroid differentiation”, Nucleic Acids Research, vol. 18, No. 9, pp. 2721-2731 (1990).Applicant
• Beutler et al., “Gene Transfer in the Treatment of Hematologic Disease”, Exp. Hematol., vol. 18, pp. 857-860 (1990).Applicant
• Ohi et al., “Construction and replication of an adeno-associated virus expression vector that contains human β-globin cDNA”, Gene, vol. 89, pp. 279-282 (1990).Applicant
• Novak et al., “High-level β-globin expression after retroviral transfer of locus activation region-containing human β-globin gene derivatives into murine erythroleukemia cells”, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 3386-3390 (May 1990).Applicant
• Desnick et al., “Human Gene Therapy: Strategies and Prospects for Inborn Errors of Metabolism”, Treatment of Genetic Diseases, pp. 239-259 (1991).Applicant
• Nienhuis et al., “Gene Transfer Into Hematopoietic Stem Cells”, Cancer, vol. 67, pp. 2700-2704 (1991).Applicant
• Samulski et al., “Targeted integration of adeno-associated virus (AAV) into human chromosome 19”, The EMBO Journal, vol. 10, No. 12, pp. 3941-3950 (1991).Applicant
• Ledley, “Clinical Considerations in the Design of Protocols for Somatic Gene Therapy”, Human Gene Therapy, vol. 2, pp. 77-83 (1991).Applicant
• Sitaric et al., “Production of a Helper-Free Recombinant Adeno-Associated Virus That Harbors Human Beta-Globin cDNA”, FASEB 6(5):6843 (Abstract) (1991).Applicant
• Walsh et al., “Gene Transfer and High Level Expression of a Human Gamma Globin Gene Mediated by a Novel Adeno-Associated Virus (AAV) Vector”, Clinical Research 39(2):325A (Abstract) (1991).Applicant
• Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells”, Current Topics in Microbiology and Immunology, vol. 158, pp. 97-129 (1992).Applicant
• Chang et al., “A 36-base-pair core sequence of locus control region enhances retrovirally transferred human β-globin gene expression”, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 3107-3110 (Apr. 1992).Applicant
• Miller, “Human gene therapy comes of age”, Nature, vol. 357, pp. 455-460 (Jun. 1992).Applicant
• Acland et al., 2001, “Gene therapy restores vision in a canine model of childhood blindness”, Nature Genetics 28:92-95.Applicant
• Bender et al., 1989, “A Majority of Mice Show Long-Term Expression of a Human β-Globin Gene after Retrovirus Transfer into Hematopoietic Stem Cells”, Molec. And Cell. Biology 9(4):1426-1434.Applicant
• Herzog et al., 1999, “Long term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector”, Nature Medicine 5(1):56-63.Applicant
• Leboulch et al., 1994, “Mutagenesis of Retroviral vectors transducing human β-globin locus control region derivatives results in stable transmission of an active transcriptional structure”, EMBO J. 13(13):3065-3076.Applicant
• Malik et al., 1997, “Recombinant adeno-associated virus mediated a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line”, J. Virol. 71(3):1776-1783.Applicant
• Ponnazhagan et al., 1997, “Adeno-associated virus type 2-mediated transduction of murine hematopietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo”, J. Virol. 71(4):3098-3104.Applicant
• Key et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genetics Mar. 2000; 24:257-261.Applicant
• Snyder et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. Jan. 1999;5(1):64-70.Applicant
• Wang et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther. Feb. 2000;1(2):154-8.Applicant